Kaiser Permanente to Evaluate Neopath's AutoPap 300 QC System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

REDMOND, Wash--NeoPath Inc has signed an agreement with Kaiser Permanente to install AutoPap 300 QC Systems at its Northern California facility. Following a successful evaluation, Kaiser Permanente anticipates making the technology available to its nearly 2.5 million Northern California members.

REDMOND, Wash--NeoPath Inc has signed an agreement with KaiserPermanente to install AutoPap 300 QC Systems at its Northern Californiafacility. Following a successful evaluation, Kaiser Permanenteanticipates making the technology available to its nearly 2.5million Northern California members.

The AutoPap System rescreens Pap smear slides initially classifiedas normal, using high-speed image processing computers, videoimaging technology, and image interpretation software. In clinicaltrials in US laboratories, the system improved the detection rateof false-negative smears.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content